Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Department of Radiological Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. wpope@mednet.ucla.edu
Patients with recurrent gliomas (n = 14) were treated with bevacizumab and carboplatin, cpt-11, or etoposide. Follow-up MRI scans were obtained 2 to 6 weeks after initiation of treatment. Contrast-enhancing tumor shrank in 7 patients, with reductions evident in as little as 2 weeks after initiation of therapy. Treatment seemed more effective for heterogeneously enhancing tumor compared with solidly enhancing tumor.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on